Altimmune Reports Pivotal MASH Trial Results for Pemvidutide

source:

[1] Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript | Seeking Alpha (https://seekingalpha.com/article/4854721-alti ...)

Altimmune Reports Pivotal MASH Trial Results for Pemvidutide

Related News

BlackSky Stock Gains 80% as Gen-3 Satellite Goes Live

Google's Dual AI Strategy Wins as OpenAI User Growth Stalls

China's $1.076T Trade Surplus Fuels Yuan Appreciation Bets